C3 glomerulonephritis
MONDO:0013892Glomerulonephritis characterized by C3 accumulation with little or absent deposition of immunoglobulin, in the absence of ultrastructural electron-dense transformation seen in dense deposit disease.
Also known as: complement-mediated membranoproliferative glomerulonephritis, nephropathy due to CFHR5 deficiency, CFHR5 deficiency
10 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC